查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1984153

腦部疾病診斷方式及軟體市場：依軟體類型、影像方式、疾病適應症、部署方法、通路及最終用戶分類－2026-2032年全球市場預測

Brain Disease Modalities & Software Market by Software Type, Imaging Modality, Disease Indication, Deployment Mode, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，腦疾病診斷和軟體市場價值將達到 152.8 億美元，到 2026 年將成長到 162.7 億美元，到 2032 年將達到 244.4 億美元，複合年成長率為 6.93%。

主要市場統計數據
基準年 2025 152.8億美元
預計年份：2026年 162.7億美元
預測年份 2032 244.4億美元
複合年成長率 (%) 6.93%

全面概述了診斷影像技術、智慧軟體和臨床需求的創新如何交會融合，從而重塑腦部疾病的診斷和治療。

先進影像技術、智慧軟體和不斷發展的臨床路徑的融合正在重塑我們檢測、監測和管理腦部疾病的方式。本執行摘要整合了影響神經系統疾病診斷和決策生態系統的關鍵變革促進因素，並將技術創新與不斷變化的臨床需求和監管要求聯繫起來。醫療設備製造商、軟體開發商、臨床網路和研究機構等相關人員正在尋求一個互通性、數據可靠性和演算法透明度與診斷靈敏度同等重要的環境。

多模態成像、演算法智慧和分散式醫療服務技術的整合如何重新定義臨床價值和競爭差異化。

隨著計算方法的成熟、影像能力的多元化以及醫療服務分散化，腦部疾病診斷和軟體領域正經歷著變革性的轉變。在所有顯像模式下，高解析度採集、多模態融合和先進的後處理的結合，使得以往在常規工作流程中難以檢測到的生物標記得以測量。攜帶式平台和訊號處理技術的改進正在重塑電診斷和功能測試技術，而混合成像方法則能夠對神經退化性疾病和急性神經系統疾病進行更精確的表現型分析。

本分析探討了 2025 年的價格調整如何重塑整個神經診斷硬體和軟體生態系統的籌資策略、供應鏈韌性和部署選擇。

2025年關稅政策的變化為神經技術領域的全球供應鏈、籌資策略和跨境服務交付帶來了新的考量。針對特定類型醫療設備和軟體相關硬體組件的關稅促使製造商和經銷商重新評估籌資策略，他們正在考慮近岸外包、組件替代和合約保障措施，以降低成本波動風險。分階段實施的關稅不僅影響資本設備，也影響相關的服務模式，因為它們會影響本地部署設備和雲端服務的部署選擇。

將影像方式、軟體類型、疾病適應症、最終用戶環境、部署模型和通路聯繫起來的詳細觀點有助於制定產品策略。

了解市場區隔對於確定產品開發優先順序、最佳化商業化策略以及使臨床檢驗工作與最終用戶需求保持一致至關重要。在影像學領域，診斷路徑包括電腦斷層掃描（CT）（包括常規CT和頻譜CT）；腦電圖（EEG）（分為攜帶式和常規EEG）；擴散張量成像（DTI）；磁振造影（MRI）（包括功能性磁振造影（fMRI ）和結構磁振造影（sMRI））；腦磁圖（MEG）（分為誘發電位和靜息態MEG）；正子斷層掃描（PET）（包括澱粉樣蛋白和FDG示蹤劑）；以及從高解析度成像到經顱都卜勒超音波的超音波方法。每種成像方式都有其獨特的資料特徵、臨床工作流程和整合挑戰，這些都會影響軟體的設計和部署。

受監管、基礎設施和支付方多樣性的驅動，美洲、歐洲、中東和非洲以及亞太地區的區域趨勢正在影響技術的採用和商業化。

區域趨勢持續對技術採納路徑、監管預期和夥伴關係模式產生重大影響。在美洲，以商業為導向的報銷框架備受重視，這有助於快速實用化和早期採用檢驗的診斷方法，尤其是在先進的醫院系統和專科診所。該地區強大的研究基礎設施也支持合作進行的臨床和多中心檢驗研究，這些研究成果通常用於更廣泛的監管申報和商業化宣傳活動。

面向神經診斷和軟體供應商的策略行動和夥伴關係模式，旨在推動技術差異化、臨床檢驗和可擴展的商業化

在腦疾病診斷和軟體領域，主要企業正透過互補策略實現差異化競爭，這些策略融合了技術創新、臨床證據的生成以及夥伴關係生態系統。許多成熟的醫療設備製造商正在擴展其成像平台，為其嵌入式分析功能並增強連接性；而專業的軟體公司則專注於擴充性的人工智慧流程和雲端原生服務，並將互通性和合規性放在首位。新興技術供應商，即從學術研究領域衍生而來的企業，正憑藉新型生物標記、訊號處理技術的進步以及旨在加速臨床工作流程的改進型使用者介面展開競爭。

為供應商提供切實可行的策略重點和實施程序，以加快部署速度，確保合規性，並在各種醫療保健環境中提供可衡量的臨床價值。

在不斷變化的環境中，尋求創造價值的領導者必須協調其在技術、臨床檢驗、監管準備和商業性執行方面的策略。首先，他們必須優先考慮產品設計的互通性和模組化，以促進產品與各種醫院和診所基礎設施的整合，從而實現快速部署並降低最終用戶的整體擁有成本。同時，他們必須投資於清晰的演算法管治框架，以支持可解釋性、減少偏差和生命週期管理，從而滿足日益嚴格的監管要求並增強臨床醫生的信心。

結合專家訪談、第二手資料整合和檢驗等穩健的混合方法研究途徑，為實用可靠的研究結果奠定了基礎。

本報告的分析是基於一種綜合調查方法，該方法結合了初步研究、嚴謹的二手資訊分析和方法論三角驗證，以確保分析的可靠性。初步研究包括對臨床負責人、技術架構師、採購專家和監管顧問進行結構化訪談，以獲取關於技術採納促進因素、實施挑戰和證據要求的第一手觀點。這些專家的意見提供了關於臨床工作流程、資料互通性限制以及對實際性能預期等方面的細緻背景資訊。

此總結重點闡述了技術成熟度、臨床證據和適應性商業化如何決定長期臨床影響和採用軌跡。

一項整合了技術趨勢、監管變化和區域發展的分析表明，未來診斷準確性和臨床決策支援將與營運適應性和可驗證的臨床價值日益緊密地交織在一起。影像技術和演算法系統正從概念驗證階段邁向能夠影響臨床路徑的實用化工具，前提是它們必須具備嚴格的檢驗、可解釋的性能特徵以及考慮區域限制的部署模型。不斷變化的收費政策、法規和支付方期望的累積影響凸顯了製定穩健的商業策略和高度適應性的產品架構的必要性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 腦疾病診斷方式及軟體市場：依軟體類型分類

  • 基於人工智慧的軟體
    • 深度學習演算法
    • 機器學習演算法
  • 臨床決策支援軟體
  • 診斷軟體
    • 影像分析軟體
    • 分割軟體
  • 監控軟體
    • 神經生理監測
    • 遠端患者監護
  • 遠端醫療平台
  • 工作流程管理軟體

第9章 依影像方法分類的腦部疾病診斷模式與軟體市場

  • 電腦斷層掃描
    • 常規CT
    • 頻譜CT
  • 腦電圖（EEG）
    • 攜帶式腦電圖（EEG）
    • 常規腦電圖
  • 磁振造影
    • 擴散張量造影
    • 功能性磁振造影
    • 結構磁振造影
  • 腦磁圖
    • 誘發反應
    • 靜止狀態
  • 正子斷層掃描
    • 澱粉樣蛋白PET
    • FDG-PET
  • 超音波
    • 高解析度
    • 經顱都卜勒

第10章：腦部疾病診斷方式及軟體市場：依疾病適應症分類

  • 阿茲海默症
  • 癲癇
    • 局部癲癇發作
    • 整體癲癇發作
  • 多發性硬化症
  • 帕金森氏症
  • 中風
    • 出血性中風
    • 缺血性中風
  • 創傷性腦損傷
    • 輕度腦外傷
    • 嚴重創傷性腦損傷

第11章 腦疾病診斷方式及軟體市場：依部署模式分類

  • 基於雲端的
  • 混合
  • 現場

第12章 腦疾病診斷方式及軟體市場：依通路分類

  • 直銷
  • 銷售代理
  • 線上平台

第13章 腦疾病診斷方式與軟體市場：依最終使用者分類

  • 門診手術中心
  • 診所
    • 神經科診所
    • 復健診所
  • 診斷影像中心
  • 醫院
    • 私立醫院
    • 公立醫院
  • 研究機構

第14章 腦疾病診斷方式與軟體市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章：腦疾病診斷方式與軟體市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 腦疾病診斷方式與軟體市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國腦疾病診斷方式與軟體市場

第18章：中國腦疾病診斷方式及軟體市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Aspect Imaging Ltd.
  • Brainomix Limited
  • Canon Medical Systems Corporation
  • Carestream Health, Inc.
  • Esaote SpA
  • Fujifilm Holdings Corporation
  • General Electric Company,
  • Imaging Biometrics LLC
  • International Business Machines Corporation
  • IXICO plc.
  • Koninklijke Philips NV,
  • MIM Software, Inc.
  • Quantib BV
  • ScienceSoft USA Corporation
  • Siemens Healthineers AG
  • VUNO Inc.
Product Code: MRR-5C6F41F5AF8F

The Brain Disease Modalities & Software Market was valued at USD 15.28 billion in 2025 and is projected to grow to USD 16.27 billion in 2026, with a CAGR of 6.93%, reaching USD 24.44 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 15.28 billion
Estimated Year [2026] USD 16.27 billion
Forecast Year [2032] USD 24.44 billion
CAGR (%) 6.93%

Comprehensive orientation to the intersection of imaging innovation, intelligent software, and clinical imperatives reshaping diagnosis and management of brain disorders

The convergence of advanced imaging modalities, intelligent software, and evolving clinical pathways is reshaping how brain diseases are detected, monitored, and managed. This executive summary synthesizes the critical vectors of change affecting diagnostic and decision-support ecosystems for neurological conditions, integrating technological innovation with shifting clinical needs and regulatory scrutiny. Stakeholders across device manufacturers, software developers, clinical networks, and research institutions are navigating an environment where interoperability, data fidelity, and algorithmic transparency are as consequential as diagnostic sensitivity.

Clinical demand is increasingly focused on tools that deliver actionable insights at the point of care and that scale across diverse care settings. Simultaneously, the proliferation of artificial intelligence and deep learning architectures has introduced new performance thresholds and design imperatives for software intended to support clinicians. As a result, organizations must reconcile the promise of higher diagnostic confidence with the operational realities of deployment, data governance, and long-term clinical validation.

This introduction frames the subsequent analysis by outlining the technological building blocks, the stakeholder dynamics that drive adoption, and the regulatory and reimbursement contexts that now exert significant influence over product roadmaps. The aim is to provide a clear analytic lens for executives seeking to align investment decisions with clinical value, implementation feasibility, and sustainable competitive positioning.

How converging advances in multimodal imaging, algorithmic intelligence, and decentralized care delivery are redefining clinical value and competitive differentiation

The landscape for brain disease diagnostics and software is undergoing transformative shifts as computational methods mature, imaging capabilities diversify, and care delivery decentralizes. Across imaging modalities, the combination of higher-resolution acquisition, multimodal fusion, and advanced post-processing has made previously latent biomarkers measurable in routine workflows. Electrodiagnostic and functional techniques are being reimagined through ambulatory platforms and improved signal processing, while hybrid imaging approaches enable more precise phenotyping of neurodegenerative and acute neurological conditions.

Software advances have been equally disruptive. The integration of deep learning and machine learning techniques into clinical decision support and diagnostic software has expanded the scope of automated interpretation, lesion detection, and prognosis modeling. These algorithmic systems are increasingly validated against multi-institutional datasets and are moving toward regulatory acceptance frameworks that demand explainability and reproducibility. Workflow management and telehealth platforms are bridging gaps between imaging centers, clinics, and tertiary care hospitals, enabling remote interpretation, real-time monitoring, and collaborative care models.

Concurrently, other structural forces are accelerating change: tighter regulatory scrutiny around AI-based medical devices, the emergence of cloud and hybrid deployment architectures, and the demand for standardized data exchange are all reshaping product architectures. As providers seek to optimize patient throughput and clinicians demand more intuitive interfaces, vendors must prioritize modular solutions that align with diverse end-user environments while maintaining robust data governance. Taken together, these shifts are redefining competitive differentiation from siloed product features toward ecosystem interoperability and sustained clinical evidence generation.

Analyzing how 2025 tariff adjustments reshaped procurement strategies, supply chain resilience, and deployment choices across neurodiagnostic hardware and software ecosystems

Tariff policy changes in 2025 introduced new considerations for global supply chains, procurement strategies, and cross-border service delivery within the neurotechnology landscape. Tariffs aimed at certain classes of medical equipment and software-related hardware components have driven a reassessment of sourcing strategies, with manufacturers and distributors examining nearshoring, component substitution, and contractual safeguards to mitigate cost volatility. The impact extends beyond capital equipment to associated service models, as tiered duties influence deployment choices between on-premise appliances and cloud-enabled services.

In response, organizations have accelerated supply chain segmentation to preserve critical capabilities while limiting exposure to tariff-driven price shifts. Contract renegotiations, more conservative inventory strategies, and selective supplier diversification have become commonplace as vendor and provider organizations seek to maintain continuity of clinical services. For software providers that bundle hardware-dependent solutions, tariffs have prompted a re-evaluation of licensing structures and greater emphasis on subscription and cloud-native models that decouple end-user costs from hardware procurement cycles.

Moreover, tariff-induced pressures have highlighted the value of adaptable deployment modes, including hybrid solutions that allow sensitive data processing to occur locally while leveraging cloud services for non-sensitive analytics and updates. For health systems operating across jurisdictions, tariff considerations are now embedded in procurement frameworks alongside clinical performance criteria and regulatory compliance. Looking ahead, resilience planning that incorporates trade policy scenarios will be essential for sustaining product rollouts and preserving margins in a landscape where geopolitical and economic levers can rapidly alter cost equations.

Deep segmentation perspective that connects imaging modalities, software types, disease indications, end-user environments, deployment modes, and distribution pathways to inform product strategy

Understanding segmentation is essential for framing product development priorities, tailoring commercialization approaches, and aligning clinical validation efforts with end-user needs. In imaging modalities, diagnostic pathways encompass computed tomography with its conventional and spectral variants, electroencephalography differentiated into ambulatory and routine formats, magnetic resonance imaging that includes diffusion tensor imaging, functional MRI, and structural MRI, magnetoencephalography split into evoked response and resting-state methods, positron emission tomography characterized by amyloid and FDG tracers, and ultrasound approaches ranging from high-resolution imaging to transcranial Doppler assessments. Each modality presents distinct data characteristics, clinical workflows, and integration challenges that influence software design and deployment.

On the software side, segmentation spans AI-based solutions that leverage deep learning and machine learning algorithms, clinical decision support platforms, diagnostic software such as image analysis and segmentation tools, monitoring software divided into neurophysiological monitoring and remote patient monitoring, telehealth platforms, and workflow management solutions. The technical architecture and validation pathways differ markedly between algorithmic components intended for autonomous interpretation and software that augments clinician decision-making, demanding tailored evidence dossiers and interoperability standards.

Disease indication segmentation covers a spectrum of neurological disorders including Alzheimer's disease, epilepsy with focal onset and generalized onset subtypes, multiple sclerosis, Parkinson's disease, stroke encompassing hemorrhagic and ischemic presentations, and traumatic brain injury with mild and severe classifications. Patient pathways, biomarker relevance, and the balance between acute versus longitudinal monitoring shape diagnostic priorities across these indications. End-user segmentation stretches across ambulatory surgical centers, clinics with neurology and rehabilitation subtypes, diagnostic imaging centers, hospitals with private and public distinctions, and research institutes engaged in translational science. Deployment modes include cloud-based, hybrid, and on-premise architectures, each presenting different trade-offs in latency, data sovereignty, and maintenance overhead. Distribution channels run from direct sales to distributors and online platforms, influencing go-to-market cadence, after-sales support models, and partner enablement strategies. Integrating these layers of segmentation is critical for designing product roadmaps that respond to clinical workflows, regulatory requirements, and the commercial dynamics of diverse healthcare settings.

Regional dynamics shaping adoption and commercialization across the Americas, Europe Middle East & Africa, and Asia-Pacific driven by regulation, infrastructure, and payer diversity

Regional dynamics continue to exert a pronounced influence on adoption pathways, regulatory expectations, and partnership models. In the Americas, healthcare delivery structures emphasize rapid translation of validated diagnostics and commercially oriented reimbursement frameworks that facilitate early adoption, particularly within advanced hospital systems and specialist clinics. The region's sizable research infrastructure also supports clinical collaborations and multicenter validation studies that are frequently leveraged for broader regulatory submissions and commercialization campaigns.

Europe, the Middle East & Africa present a heterogeneous environment where regulatory harmonization efforts coexist with significant national-level variation. European regulatory rigor and data protection norms have incentivized vendors to prioritize algorithmic transparency and robust clinical evidence, while markets in the Middle East and Africa exhibit opportunities for leapfrogging to cloud-enabled services in contexts where centralized imaging infrastructure is limited. Accessibility, cost-containment pressures, and diverse payer models necessitate adaptable pricing strategies and flexible deployment options to achieve broader adoption across this expansive region.

The Asia-Pacific region is characterized by rapid infrastructure expansion, strong government-led investments in healthcare modernization, and vibrant local innovation ecosystems. Diverse payer structures and varying levels of clinical specialization drive a dual approach from vendors: offering scalable cloud-based solutions for urban centers with advanced digital infrastructure while providing resilient on-premise or hybrid systems for facilities with constrained connectivity. Collaboration with regional research institutes and localization of validation studies often underpin successful market entry and uptake across Asia-Pacific markets.

Strategic company behaviors and partnership models driving technological differentiation, clinical validation, and scalable commercialization across neurodiagnostic and software vendors

Key companies operating within the brain disease modalities and software space are differentiating through complementary strategies that combine technological innovation, clinical evidence generation, and partnership ecosystems. Many established medical device manufacturers are augmenting imaging platforms with embedded analytics and enhanced connectivity, while specialized software firms focus on scalable AI pipelines and cloud-native services that prioritize interoperability and regulatory readiness. Emerging technology providers, frequently spun out from academic research, are competing on novel biomarkers, signal processing advances, or improved user interfaces designed to accelerate clinical workflows.

Strategic collaborations and licensing agreements between hardware vendors and software developers have become central to accelerating time-to-clinic and expanding distribution reach. Additionally, partnerships with clinical networks and research institutes are increasingly used to secure real-world validation and to navigate complex reimbursement pathways. Companies are also investing in post-market surveillance and continuous learning systems to ensure algorithmic performance remains robust across diverse patient populations and imaging platforms.

Operationally, successful organizations emphasize modular product architectures that can be deployed on-premise, in hybrid configurations, or via cloud services, thereby accommodating the heterogeneous needs of hospitals, clinics, and diagnostic centers. Commercial excellence is underpinned by comprehensive support models, professional services for implementation, and training programs that reduce clinician friction during adoption. Collectively, these strategic choices reflect an industry that is balancing innovation with pragmatic approaches to scale, compliance, and clinical acceptance.

Practical strategic priorities and implementation steps for vendors to accelerate adoption, ensure compliance, and deliver measurable clinical value across diverse care settings

Leaders seeking to capture value in this evolving landscape should align their strategies across technology, clinical validation, regulatory preparedness, and commercial execution. First, prioritize interoperability and modularity in product design to facilitate integration into heterogeneous hospital and clinic infrastructures, enabling faster deployments and lower total cost of ownership for end users. Concurrently, invest in clear algorithmic governance frameworks that support explainability, bias mitigation, and lifecycle management to meet increasingly stringent regulatory expectations and to build clinician trust.

Second, embed clinical evidence generation into commercialization roadmaps by forging early partnerships with treatment centers and research institutes to produce reproducible, peer-reviewed outcomes. These collaborations should extend beyond retrospective validation into prospective, real-world studies that demonstrate clinical utility and workflow efficiency. Third, adopt flexible deployment strategies that permit cloud, hybrid, and on-premise configurations to address data sovereignty, latency, and connectivity constraints; this flexibility will be crucial when navigating tariff-driven procurement dynamics or region-specific infrastructure limitations.

Fourth, refine go-to-market approaches by tailoring distribution and pricing models to end-user segmentation. Direct engagement is often essential for large hospitals and health systems, whereas distributors and online channels can accelerate penetration within diagnostic centers and ambulatory networks. Finally, build a robust post-deployment support ecosystem that includes training, maintenance, and outcome-tracking services to sustain utilization, gather post-market data, and create defensible competitive advantage over time. Executing on these recommendations will require cross-functional alignment and an emphasis on measurable clinical outcomes as the primary metric of success.

Robust mixed-methods research approach combining primary expert engagements, secondary evidence synthesis, and triangulated validation to underpin practical, trustworthy insights

The analysis underpinning this report draws on an integrated research methodology that combines primary engagements, rigorous secondary intelligence, and methodological triangulation to ensure analytical robustness. Primary research included structured interviews with clinical leaders, technical architects, procurement specialists, and regulatory advisors to capture firsthand perspectives on adoption drivers, implementation challenges, and evidence requirements. These expert inputs offered nuanced context on clinical workflows, data interoperability constraints, and real-world performance expectations.

Secondary research synthesized peer-reviewed literature, technology whitepapers, regulatory guidance documents, and clinical practice recommendations to establish a foundation of domain knowledge and to validate technical assertions. Where applicable, public clinical registries and standards bodies' publications were referenced to ensure alignment with prevailing clinical and technical norms. Qualitative insights were complemented by structured comparative assessments of technology features, deployment modes, and validation practices to articulate relative strengths and limitations across solution classes.

Data integrity was maintained through methodological triangulation, cross-checking stakeholder testimonies against published evidence and regulatory documents. The research process emphasized transparency in assumption-setting, careful delineation of data sources, and the use of consensus approaches when reconciling divergent expert views. Ethical considerations and data privacy compliance were observed throughout primary data collection, and findings were synthesized to support practical decision-making for industry leaders and healthcare providers.

Concluding synthesis highlighting how technology maturity, clinical evidence, and adaptive commercialization will determine long-term clinical impact and adoption trajectories

The synthesis of technological trends, regulatory shifts, and regional dynamics points to a future in which diagnostic precision and clinical decision support are increasingly interwoven with operational adaptability and demonstrable clinical value. Imaging modalities and algorithmic systems are moving beyond proof-of-concept to operationalized tools that can influence care pathways, provided they are accompanied by rigorous validation, explainable performance characteristics, and deployment models attuned to local constraints. The cumulative effects of tariff policies, regulatory evolution, and payer expectations underscore the need for resilient commercial strategies and adaptable product architectures.

For healthcare providers, the imperative is to adopt solutions that integrate seamlessly with existing workflows while offering tangible improvements in diagnostic confidence and efficiency. For vendors, success will hinge on balancing innovation with disciplined clinical evidence generation, interoperability commitments, and comprehensive support structures that facilitate adoption across varied end-user environments. Ultimately, the interplay of technology, evidence, and execution will determine which solutions achieve sustainable clinical impact and market acceptance. Stakeholders who proactively address these dimensions will be best positioned to advance patient outcomes and to realize long-term strategic objectives.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Brain Disease Modalities & Software Market, by Software Type

  • 8.1. Ai Based Software
    • 8.1.1. Deep Learning Algorithms
    • 8.1.2. Machine Learning Algorithms
  • 8.2. Clinical Decision Support Software
  • 8.3. Diagnostic Software
    • 8.3.1. Image Analysis Software
    • 8.3.2. Segmentation Software
  • 8.4. Monitoring Software
    • 8.4.1. Neurophysiological Monitoring
    • 8.4.2. Remote Patient Monitoring
  • 8.5. Telehealth Platform
  • 8.6. Workflow Management Software

9. Brain Disease Modalities & Software Market, by Imaging Modality

  • 9.1. Computed Tomography
    • 9.1.1. Conventional Ct
    • 9.1.2. Spectral Ct
  • 9.2. Electroencephalography
    • 9.2.1. Ambulatory Eeg
    • 9.2.2. Routine Eeg
  • 9.3. Magnetic Resonance Imaging
    • 9.3.1. Diffusion Tensor Imaging
    • 9.3.2. Functional Mri
    • 9.3.3. Structural Mri
  • 9.4. Magnetoencephalography
    • 9.4.1. Evoked Response
    • 9.4.2. Resting State
  • 9.5. Positron Emission Tomography
    • 9.5.1. Amyloid Pet
    • 9.5.2. Fdg Pet
  • 9.6. Ultrasound
    • 9.6.1. High Resolution
    • 9.6.2. Transcranial Doppler

10. Brain Disease Modalities & Software Market, by Disease Indication

  • 10.1. Alzheimer's Disease
  • 10.2. Epilepsy
    • 10.2.1. Focal Onset
    • 10.2.2. Generalized Onset
  • 10.3. Multiple Sclerosis
  • 10.4. Parkinson's Disease
  • 10.5. Stroke
    • 10.5.1. Hemorrhagic Stroke
    • 10.5.2. Ischemic Stroke
  • 10.6. Traumatic Brain Injury
    • 10.6.1. Mild Tbi
    • 10.6.2. Severe Tbi

11. Brain Disease Modalities & Software Market, by Deployment Mode

  • 11.1. Cloud Based
  • 11.2. Hybrid
  • 11.3. On Premise

12. Brain Disease Modalities & Software Market, by Distribution Channel

  • 12.1. Direct
  • 12.2. Distributors
  • 12.3. Online Platforms

13. Brain Disease Modalities & Software Market, by End User

  • 13.1. Ambulatory Surgical Centers
  • 13.2. Clinics
    • 13.2.1. Neurology Clinics
    • 13.2.2. Rehabilitation Clinics
  • 13.3. Diagnostic Imaging Centers
  • 13.4. Hospitals
    • 13.4.1. Private Hospitals
    • 13.4.2. Public Hospitals
  • 13.5. Research Institutes

14. Brain Disease Modalities & Software Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Brain Disease Modalities & Software Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Brain Disease Modalities & Software Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Brain Disease Modalities & Software Market

18. China Brain Disease Modalities & Software Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Aspect Imaging Ltd.
  • 19.6. Brainomix Limited
  • 19.7. Canon Medical Systems Corporation
  • 19.8. Carestream Health, Inc.
  • 19.9. Esaote S.p.A.
  • 19.10. Fujifilm Holdings Corporation
  • 19.11. General Electric Company,
  • 19.12. Imaging Biometrics LLC
  • 19.13. International Business Machines Corporation
  • 19.14. IXICO plc.
  • 19.15. Koninklijke Philips N.V.,
  • 19.16. MIM Software, Inc.
  • 19.17. Quantib B.V.
  • 19.18. ScienceSoft USA Corporation
  • 19.19. Siemens Healthineers AG
  • 19.20. VUNO Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY SOFTWARE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY IMAGING MODALITY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY DISEASE INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY DEPLOYMENT MODE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY SOFTWARE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY AI BASED SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY AI BASED SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY AI BASED SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY AI BASED SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY DEEP LEARNING ALGORITHMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY DEEP LEARNING ALGORITHMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY DEEP LEARNING ALGORITHMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY MACHINE LEARNING ALGORITHMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY MACHINE LEARNING ALGORITHMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY MACHINE LEARNING ALGORITHMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY CLINICAL DECISION SUPPORT SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY CLINICAL DECISION SUPPORT SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY CLINICAL DECISION SUPPORT SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY DIAGNOSTIC SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY DIAGNOSTIC SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY DIAGNOSTIC SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY DIAGNOSTIC SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY IMAGE ANALYSIS SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY IMAGE ANALYSIS SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY IMAGE ANALYSIS SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY SEGMENTATION SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY SEGMENTATION SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY SEGMENTATION SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY MONITORING SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY MONITORING SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY MONITORING SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY MONITORING SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY NEUROPHYSIOLOGICAL MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY NEUROPHYSIOLOGICAL MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY NEUROPHYSIOLOGICAL MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY REMOTE PATIENT MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY REMOTE PATIENT MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY REMOTE PATIENT MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY TELEHEALTH PLATFORM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY TELEHEALTH PLATFORM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY TELEHEALTH PLATFORM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY WORKFLOW MANAGEMENT SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY WORKFLOW MANAGEMENT SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY WORKFLOW MANAGEMENT SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY IMAGING MODALITY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY COMPUTED TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY CONVENTIONAL CT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY CONVENTIONAL CT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY CONVENTIONAL CT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY SPECTRAL CT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY SPECTRAL CT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY SPECTRAL CT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY ELECTROENCEPHALOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY ELECTROENCEPHALOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY ELECTROENCEPHALOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY ELECTROENCEPHALOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY AMBULATORY EEG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY AMBULATORY EEG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY AMBULATORY EEG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY ROUTINE EEG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY ROUTINE EEG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY ROUTINE EEG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY DIFFUSION TENSOR IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY DIFFUSION TENSOR IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY DIFFUSION TENSOR IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY FUNCTIONAL MRI, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY FUNCTIONAL MRI, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY FUNCTIONAL MRI, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY STRUCTURAL MRI, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY STRUCTURAL MRI, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY STRUCTURAL MRI, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY MAGNETOENCEPHALOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY MAGNETOENCEPHALOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY MAGNETOENCEPHALOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY MAGNETOENCEPHALOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY EVOKED RESPONSE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY EVOKED RESPONSE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY EVOKED RESPONSE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY RESTING STATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY RESTING STATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY RESTING STATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY AMYLOID PET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY AMYLOID PET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY AMYLOID PET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY FDG PET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY FDG PET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY FDG PET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY ULTRASOUND, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY ULTRASOUND, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY ULTRASOUND, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY HIGH RESOLUTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY HIGH RESOLUTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY HIGH RESOLUTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY TRANSCRANIAL DOPPLER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY TRANSCRANIAL DOPPLER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY TRANSCRANIAL DOPPLER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY ALZHEIMER'S DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY ALZHEIMER'S DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY ALZHEIMER'S DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY EPILEPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY EPILEPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY EPILEPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY EPILEPSY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY FOCAL ONSET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY FOCAL ONSET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY FOCAL ONSET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY GENERALIZED ONSET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY GENERALIZED ONSET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY GENERALIZED ONSET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY MULTIPLE SCLEROSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY MULTIPLE SCLEROSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY PARKINSON'S DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY PARKINSON'S DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY STROKE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY STROKE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY STROKE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY STROKE, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY HEMORRHAGIC STROKE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY HEMORRHAGIC STROKE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY HEMORRHAGIC STROKE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY ISCHEMIC STROKE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY ISCHEMIC STROKE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY ISCHEMIC STROKE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY TRAUMATIC BRAIN INJURY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY TRAUMATIC BRAIN INJURY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY TRAUMATIC BRAIN INJURY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY TRAUMATIC BRAIN INJURY, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY MILD TBI, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY MILD TBI, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY MILD TBI, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY SEVERE TBI, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY SEVERE TBI, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY SEVERE TBI, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY DEPLOYMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY CLOUD BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY CLOUD BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY CLOUD BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY HYBRID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY HYBRID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY HYBRID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY ON PREMISE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY ON PREMISE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY ON PREMISE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY DIRECT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY DIRECT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY DIRECT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY DISTRIBUTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY DISTRIBUTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY DISTRIBUTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY ONLINE PLATFORMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY ONLINE PLATFORMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY ONLINE PLATFORMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 172. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY NEUROLOGY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 175. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY NEUROLOGY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY NEUROLOGY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY REHABILITATION CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 178. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY REHABILITATION CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY REHABILITATION CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 181. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 183. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 184. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 185. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 186. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 187. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 188. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 189. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 191. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 192. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 194. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 195. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 197. AMERICAS BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 198. AMERICAS BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY SOFTWARE TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. AMERICAS BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY AI BASED SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 200. AMERICAS BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY DIAGNOSTIC SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 201. AMERICAS BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY MONITORING SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 202. AMERICAS BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY IMAGING MODALITY, 2018-2032 (USD MILLION)
  • TABLE 203. AMERICAS BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY COMPUTED TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 204. AMERICAS BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY ELECTROENCEPHALOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 205. AMERICAS BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 206. AMERICAS BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY MAGNETOENCEPHALOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 207. AMERICAS BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 208. AMERICAS BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 209. AMERICAS BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 210. AMERICAS BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY EPILEPSY, 2018-2032 (USD MILLION)
  • TABLE 211. AMERICAS BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY STROKE, 2018-2032 (USD MILLION)
  • TABLE 212. AMERICAS BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY TRAUMATIC BRAIN INJURY, 2018-2032 (USD MILLION)
  • TABLE 213. AMERICAS BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY DEPLOYMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 214. AMERICAS BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 215. AMERICAS BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 216. AMERICAS BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 217. AMERICAS BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 218. NORTH AMERICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 219. NORTH AMERICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY SOFTWARE TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. NORTH AMERICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY AI BASED SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 221. NORTH AMERICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY DIAGNOSTIC SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 222. NORTH AMERICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY MONITORING SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 223. NORTH AMERICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY IMAGING MODALITY, 2018-2032 (USD MILLION)
  • TABLE 224. NORTH AMERICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY COMPUTED TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 225. NORTH AMERICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY ELECTROENCEPHALOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 226. NORTH AMERICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 227. NORTH AMERICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY MAGNETOENCEPHALOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 228. NORTH AMERICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 229. NORTH AMERICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 230. NORTH AMERICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY EPILEPSY, 2018-2032 (USD MILLION)
  • TABLE 232. NORTH AMERICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY STROKE, 2018-2032 (USD MILLION)
  • TABLE 233. NORTH AMERICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY TRAUMATIC BRAIN INJURY, 2018-2032 (USD MILLION)
  • TABLE 234. NORTH AMERICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY DEPLOYMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 235. NORTH AMERICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 236. NORTH AMERICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 237. NORTH AMERICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 238. NORTH AMERICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 239. LATIN AMERICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 240. LATIN AMERICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY SOFTWARE TYPE, 2018-2032 (USD MILLION)
  • TABLE 241. LATIN AMERICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY AI BASED SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 242. LATIN AMERICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY DIAGNOSTIC SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 243. LATIN AMERICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY MONITORING SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 244. LATIN AMERICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY IMAGING MODALITY, 2018-2032 (USD MILLION)
  • TABLE 245. LATIN AMERICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY COMPUTED TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 246. LATIN AMERICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY ELECTROENCEPHALOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 247. LATIN AMERICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 248. LATIN AMERICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY MAGNETOENCEPHALOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 249. LATIN AMERICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 250. LATIN AMERICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 251. LATIN AMERICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 252. LATIN AMERICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY EPILEPSY, 2018-2032 (USD MILLION)
  • TABLE 253. LATIN AMERICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY STROKE, 2018-2032 (USD MILLION)
  • TABLE 254. LATIN AMERICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY TRAUMATIC BRAIN INJURY, 2018-2032 (USD MILLION)
  • TABLE 255. LATIN AMERICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY DEPLOYMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 256. LATIN AMERICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 257. LATIN AMERICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 258. LATIN AMERICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 259. LATIN AMERICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY SOFTWARE TYPE, 2018-2032 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY AI BASED SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY DIAGNOSTIC SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY MONITORING SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 265. EUROPE, MIDDLE EAST & AFRICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY IMAGING MODALITY, 2018-2032 (USD MILLION)
  • TABLE 266. EUROPE, MIDDLE EAST & AFRICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY COMPUTED TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 267. EUROPE, MIDDLE EAST & AFRICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY ELECTROENCEPHALOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 268. EUROPE, MIDDLE EAST & AFRICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 269. EUROPE, MIDDLE EAST & AFRICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY MAGNETOENCEPHALOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 270. EUROPE, MIDDLE EAST & AFRICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY POSITRON EMISSION TOM